Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0146 • ACR Convergence 2021
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
Akrithi Udupa¹, Catherine Sims², Poorva Apte², Megan Milne², Isaac Smith¹, D Ryan Anderson¹, Mithu Maheswaranathan², Jayanth Doss² and David Leverenz², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: The COVID-19 pandemic led to the rapid implementation of telehealth in rheumatology with unknown implications for medication toxicity lab monitoring. The purpose of this…
Abstract Number: 0230 • ACR Convergence 2021
Fatigue and Inflammation in Rheumatoid Arthritis Are Already Disconnected Before Clinical Arthritis Develops
Sarah J.H. Khidir¹, Annette H.M van der Helm-van Mil¹ and Elise van Mulligen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Fatigue is disabling and common in Rheumatoid Arthritis (RA); the causation of fatigue in RA is multidimensional and only partially explained by inflammation. The…
Abstract Number: 0282 • ACR Convergence 2021
5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
Tsz On Lam¹ and Lai-Shan Tam², ¹Prince of Wales Hospital, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is associated with higher cardiovascular disease (CVD) risk due to the underlying inflammation.It is uncertain if the excess CV risk could…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Klaus Krüger¹, Frank Behrens², Ulrich Prothmann³, Thilo Klopsch⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Jürgen Jobst⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹Rheumatological Practice Center, Munich, Germany, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, ³Knappschaftsklinikum Saar, Püttlingen, Germany, ⁴Rheumatological Practice, Neubrandenburg, Germany, ⁵Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…
Abstract Number: 0584 • ACR Convergence 2021
High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Eduard N Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder¹⁵, Willem Lems¹⁶ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Leeuwarden, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg ZWN, Almere, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵Medical Centre Leeuwarden, Leeuwarden, Netherlands, ¹⁶VUmc, Amsterdam, Netherlands
Background/Purpose: Older people are often underrepresented in trials because the generally high number of comorbid conditions (1). The objective of this abstract is to document…
Abstract Number: 0631 • ACR Convergence 2021
Provider Assessment of Telehealth Utility During COVID-19
Catherine Howe¹, Isaac Smith¹, Robert Overton², Ricardo Henao², Nicoleta Economou-Zavlanos², Jayanth Doss³, Megan Clowse⁴ and David Leverenz³, ¹Duke University Hospital, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke University, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: The COVID-19 pandemic forced the provision of telehealth care to rheumatology patients with a broader range of diagnoses and disease activity than previously studied.…
Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Marloes Verstappen¹, Hanna van Steenbergen², Pascal de Jong³ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden Univeristy Medical Center, Leiden, Netherlands, ³Erasmus MC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
Abstract Number: 0806 • ACR Convergence 2021
Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
Zafer Alman¹, Gilles Boire², Nathalie Carrier³, Ariel Masetto², Artur deBrum Fernandes⁴, Patrick Liang², Patricia L Dobkin⁵, Allard-Chamard Hugues⁶ and Sophie Roux⁷, ¹Cerrahpasa Faculty of Medicine, Istambul, Turkey, ²Universite de Sherbrooke, Sherbrooke, QC, Canada, ³CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ⁴Universite De Sherbrooke, Fleurimont, QC, Canada, ⁵McGill University, Montréal, QC, Canada, ⁶Universit de Sherbrooke, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Receiving a Rheumatoid Arthritis (RA) diagnosis presents a significant health stressor. Given that little is known about how patients cope with it, we aimed…
Abstract Number: 0825 • ACR Convergence 2021
An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial
Mikkel Ostergaard¹, Ronald van Vollenhoven², Anna Rudin³, Merete Hetland⁴, Marte S Heiberg⁵, Dan Nordström⁶, Michael Nurmohamed⁷, Bjorn Gudbjornsson⁸, Lykke Ørnbjerg⁹, Pernille Bøyesen¹⁰, Inge Olsen¹¹, Kristina Lend¹², Kim Hørslev-Petersen¹³, Till Uhlig¹⁴, Tuulikki Sokka-Isler¹⁵, Gerdur Grondal⁸, Simon Krabbe¹⁶, Joakim Lindqvist¹⁷, Inger Gjertsson¹⁸, Daniel Glinatsi⁹, Meliha Kapetanovic¹⁹, Anna-Birgitte Aga¹⁰, Francesca Faustini²⁰, Pinja Parmanne²¹, Tove Lorenzen²², Cagnotto Giovanni²³, Johan Back²⁴, Oliver Hendricks²⁵, Daisy Vedder²⁶, Tuomas Rannio²⁷, Emma Grenholm²⁸, Maud Kristine Ljoså²⁹, Eli Brodin³⁰, Hanne Merete Lindegaard³¹, Annika Söderbergh³², Milad Rizk³³, Elsa Hermansson³⁴, Per Larsson³⁵, Line Uhrenholt³⁶, Søren Andreas Just³⁷, David John Stevens³⁸, Trine Bay Laurberg³⁹, Gunnstein Bakland⁴⁰, Espen Haavardsholm⁴¹ and Jon Lampa¹⁷, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁴DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁷Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁸Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, ⁹Copenhagen Center for Arthritis Research, COPECARE, Glostrup, Denmark, ¹⁰Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ¹³King Christian X's Hospital for Rheumatic Diseases, Gråsten, Denmark, ¹⁴Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, ¹⁵University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁶Radiologisk Afdeling, Herlev Universitetshospital, Herlev, Denmark, ¹⁷Karolinska University Hospital, Stockholm, Sweden, ¹⁸Dept. of Rheumatology, Sahlgrenska University Hospital, Gothenborg, Sweden, ¹⁹Dept. of Clinical Sciences, Skåne University Hospital, Lund, Sweden, ²⁰Dept. of Medicine, Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ²¹Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ²²Dept. of Rheumatology, Silkeborg University Hospital, Silkeborg, Denmark, ²³Dept. of Clinical Sciences, Skåne University Hospital, Malmö, Sweden, ²⁴Dept. of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden, ²⁵Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²⁶Dept. of Rheumatology, Reade, Amsterdam, Netherlands, ²⁷Finland Central Hospital, Jyväskylä, Finland, ²⁸Dept. of Rheumatology, Falunl, Falun, Sweden, ²⁹Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ³⁰Dept. of Rheumatology, Haukeland University Hospital, Haukeland, Norway, ³¹Rheumatology Research Unit, Odense University Hospital, Odense, Denmark, ³²Dept. of Rheumatology, Örebro University Hospital, Örebro, Sweden, ³³Rheumatology Clinic, Västmanlands Hospital Västerås, Västerås, Sweden, ³⁴Dept. of Rheumatology, Linköping University Hospital, Linköping, Sweden, ³⁵Academic Specialist Center, Stockholm, Sweden, ³⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³⁷Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ³⁸Dept. of Rheumatology, University Hospital of Trondheim, Trondheim, Norway, ³⁹Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴⁰Dept. of Rheumatology, University Hospital of North Norway, Tromsø, Norway, ⁴¹[email protected], Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (eRA) is yet to be established. The main objectives were to assess and…
Abstract Number: 0841 • ACR Convergence 2021
Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry
Linus Risser¹, Torsten Witte², Peter Bartz-Bazzanella³, Cay Von der Decken⁴, Johannes Knitza⁵, Sándor P. Fekete⁶, Alexander Zink⁷, Georg Gauler⁸, Patrick Wurth⁹, Peer Aries¹⁰, Kirsten Karberg¹¹, Christoph Kuhn¹², Florian Schuch¹³, Susanna Späthling-Mestekemper¹⁴, Wolfgang Vorbrüggen¹⁵, Mathias Englbrecht¹⁶, Martin Welcker¹⁷ and Stefan Kleinert¹⁸, ¹Medizinische Hochschule Hannover, Hannover, Germany, ²Hannover Medical School, Hannover, Germany, ³Rhein-Maas Klinikum, Wuerselen, Germany, ⁴Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, University Hospital Erlangen, Erlangen, Germany, ⁶Department of Computer Science, TU Braunschweig, Braunschweig, Germany, ⁷Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany, ⁸rheumapraxis, Osnabrck, Germany, ⁹Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ¹⁰Rheumatologie in Hamburg, Hamburg, Germany, ¹¹Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ¹²Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹³Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ¹⁴Rheumapraxis München, München, Germany, ¹⁵Verein zur Förderung der Rheumatologie e.V., Würselen, Germany, ¹⁶Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹⁷MVZ für Rheumatologie, Planegg, Germany, ¹⁸Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA…
Abstract Number: 0995 • ACR Convergence 2021
Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
Richard Bell, Chao Yang, Caroline Brauner, Upneet Sohki, Rouxi Yuan, Bikash Mishra, Mahesh Bachu and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Zymosan (Zym) induces arthritis through TLR2- and Dectin-1-activated NK-κB signaling and inflammatory myeloid cell infiltration into the synovium of the injected joint. Innate immune…
Abstract Number: 1074 • ACR Convergence 2021
Satisfaction with a Virtual Learning Collaborative Aimed at Implementing Treat to Target (TTT) in Rheumatoid Arthritis (RA)
Jack Ellrodt¹, Josef Smolen², Theodore Pincus³, Nancy Shadick¹, Jeffrey Katz¹, Leah Santacroce¹, Jacklyn Stratton¹, DH Solomon¹, Prem Chatpar⁴, Mary Stocks⁴, Breanna Mundell⁴, Christina Downey⁵, Karina Torralba⁶, Douglas White⁷, Meggan Baudek⁷, Steven Szlembarski⁷, Sharon Barnhart⁷, Jawad Bilal⁸, Albert Redford⁸, Dylan Lee⁸, Julia Buchfuhrer⁹, Helene Kramer⁸, C. Kent Kwoh¹⁰, Michel Villatoro-Villar⁸, Asha Patnaik¹¹, Edgardo Guzman¹¹, Rebecca Trachtman¹², John Tesser¹³, Dijana Music¹⁴, Lexi Mickey¹⁵, Mona Amin¹⁶, Jeffrey Potter¹⁷, Joshua Sundhar¹⁸, Jessica Sheingold¹⁹, Juan Schmukler²⁰, Diane Horowitz²¹, Hannah Gulko²¹, Robert Quinet²², Swathi Dhulipala²³, Ronak Patel²⁴, Chandana Keshavamurthy²⁵, Guiset Carvajal²⁶, Rhonda Dunn²⁷, Bharat Kumar²⁷, Aleksander Lenert²⁷, Hanna Zembrzuska²⁷, Matthew Gebre²⁸, Petar Lenert²⁹, Allen Anandarjah³⁰, Annie Yang³⁰, Linda Grinnell-Merrick³⁰, Shadefai Goldsmith³⁰, Jonna Zelie³⁰, Leanna Wise³¹, Nicole Zagelbaum Ward³² and Jeffrey Kaine³³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Vienna, Vienna, Austria, ³Rush University Medical Center, Chicago, IL, ⁴Dr. Chatpar and Associates, LLC, Plainview, NY, ⁵Loma Linda University Medical Center, Redlands, CA, ⁶Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ⁷Gundersen Health, La Crosse, WI, ⁸University of Arizona, Phoenix, AZ, ⁹University of Arizona, Pheonix, AZ, ¹⁰University of Arizona College of Medicine, Tuscon, AZ, ¹¹Stony Brook School of Medicine, Stony Brook, NY, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ¹⁴Arizona Arthritis and Rheumatology Associates, Glendale, AZ, ¹⁵Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, ¹⁶Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, ¹⁷Arthritis & Rheumatism Associates, Wheaton, MD, ¹⁸Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, ¹⁹MedStar Georgetown University Hospital, Washington, DC, ²⁰Mount Sinai- Chicago, Chicago, IL, ²¹Northwell Health, Great Neck, NY, ²²Ochsner Health, River Ridge, LA, ²³Ochsner Clinic Foundation, River Ridge, LA, ²⁴Ochsner Health, Jefferson, LA, ²⁵Ochsner, New Orleans, LA, ²⁶University of Colorado, Colorado, CO, ²⁷University of Iowa, Iowa City, IA, ²⁸Loma Linda University Medical Center, Loma Linda, CA, ²⁹University of Iowa Medical School, Iowa City, IA, ³⁰University of Rochester, Rochester, NY, ³¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ³²LAC+USC Medical Center, Los Angeles, CA, ³³Cullowhee, NC
Background/Purpose: Learning collaboratives (LC) have been used widely for quality improvement in healthcare, and a recent 9-month in person LC was found effective for improving…
Abstract Number: 1201 • ACR Convergence 2021
Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
Steven Taylor¹, Bryant England², Joshua Baker³, Brian Sauer⁴ and John Richards⁵, ¹UPMC, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA
Background/Purpose: RA is a complex multisystem disease, which, untreated, results in debilitating joint damage, excess morbidity, and premature mortality. Previous research has demonstrated an association…
Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].